Healthcare databases may allow for greater access to real-world medical data, but they can become a risk to patients and healthcare systems if they are not considered carefully, according to a study published in Current Epidemiology Reports.
Healthcare databases may allow for greater access to real-world medical data, but they can become a risk to patients and healthcare systems if they are not considered carefully, according to a study published in Current Epidemiology Reports.
The researchers studied healthcare databases used in pharmacovigilance for quantifying adverse outcomes, methods to improve research quality, and best practices for pharmacoepidemiologic studies. They found many sources do not include information on potential risk factors affecting health outcomes, such as smoking and adherence to the medication.
Another challenge the authors encountered was the fact that some long-term outcomes, such as cancer, are difficult to study because many databases contain relatively short-term follow-up.
"The monitoring of drug safety cannot yet be delegated to smart algorithms applied to healthcare databases," Elizabeth Andrews, PhD, vice president of pharmacoepidemiology and risk management at RTI Health Solutions and co-author of the paper, said in a statement. "With all the fervor around the potential for big data, it's critical to keep in mind the substantial differences across databases in content, coding systems and practices, duration of available medical history and follow-up time, quality of outcome information, and clinical practice patterns."
The authors found that healthcare databases tend to include real-world evidence instead of data from clinical trials. This real-world data used in healthcare databases are often not verified against source records or controlled, which has both pros and cons.
"A drawback of clinical trials is that they are highly controlled and highly monitored to ensure strict adherence to protocol; however, that's not how people take drugs in the real world," Andrea V. Margulis, MD, ScD, senior research epidemiologist and co-author of the paper, said. "Real world data have problems too because they are so uncontrolled. With this report, we wanted to explore the pros and cons of working with real world data."
They concluded that using healthcare databases for some activities may not be advisable until these applications can be better targeted to “the right data sources appropriate for specific exposures and outcomes.” Unfortunately, the increasing amount of healthcare records from multiple sources increases the difficulty of targeting.
“Without appropriate care, we risk finding an overabundance of false signals and false assurance from the absence of signals, with associated consequences for patients and the healthcare system,” the authors concluded.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Suggests Walking 10K Steps Daily Improves QOL in Severe Hemophilia
April 12th 2024Among a small group of patients with severe hemophilia, researchers found that getting in more than 10,000 steps each day was linked to significant improvements in perceived physical health and quality of life (QOL).
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
What We’re Reading: Telehealth Debate; STD Rise Among Older Adults; PFAS Limits in Water
April 10th 2024Lawmakers are under pressure to decide the fate of COVID-era telehealth payment changes; the CDC reports an alarming increase in sexually transmitted disease (STD) cases among Americans 55 years and older; new regulations aim to reduce harmful exposure to per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals.”
Read More